Gibney GT - Search Results

1

Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor.

Johnson DB, Flaherty KT, Weber JS, Infante JR, Kim KB, Kefford RF, Hamid O, Schuchter L, Cebon J, Sharfman WH, McWilliams RR, Sznol M, Lawrence DP, Gibney GT, Burris HA 3rd, Falchook GS, Algazi A, Lewis K, Long GV, Patel K, Ibrahim N, Sun P, Little S, Cunningham E, Sosman JA, Daud A, Gonzalez R. Johnson DB, et al. Among authors: gibney gt. J Clin Oncol. 2014 Nov 20;32(33):3697-704. doi: 10.1200/JCO.2014.57.3535. Epub 2014 Oct 6. J Clin Oncol. 2014. PMID: 25287827 Free PMC article. Clinical Trial.

2

Multi-omic profiling reveals discrepant immunogenic properties and a unique tumor microenvironment among melanoma brain metastases.

In GK, Ribeiro JR, Yin J, Xiu J, Bustos MA, Ito F, Chow F, Zada G, Hwang L, Salama AKS, Park SJ, Moser JC, Darabi S, Domingo-Musibay E, Ascierto ML, Margolin K, Lutzky J, Gibney GT, Atkins MB, Izar B, Hoon DSB, VanderWalde AM. In GK, et al. Among authors: gibney gt. NPJ Precis Oncol. 2023 Nov 14;7(1):120. doi: 10.1038/s41698-023-00471-z. NPJ Precis Oncol. 2023. PMID: 37964004 Free PMC article.

3

Extending the reach of BRAF-targeted cancer therapy.

Gibney GT, Sondak VK. Gibney GT, et al. Lancet. 2012 May 19;379(9829):1858-9. doi: 10.1016/S0140-6736(12)60610-2. Lancet. 2012. PMID: 22608322 No abstract available.

4

Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma.

Pilon-Thomas S, Kuhn L, Ellwanger S, Janssen W, Royster E, Marzban S, Kudchadkar R, Zager J, Gibney G, Sondak VK, Weber J, Mulé JJ, Sarnaik AA. Pilon-Thomas S, et al. J Immunother. 2012 Oct;35(8):615-20. doi: 10.1097/CJI.0b013e31826e8f5f. J Immunother. 2012. PMID: 22996367 Free PMC article. Clinical Trial.

5

NRAS mutant melanoma: biological behavior and future strategies for therapeutic management.

Fedorenko IV, Gibney GT, Smalley KS. Fedorenko IV, et al. Among authors: gibney gt. Oncogene. 2013 Jun 20;32(25):3009-18. doi: 10.1038/onc.2012.453. Epub 2012 Oct 15. Oncogene. 2013. PMID: 23069660 Free PMC article. Review.

6

Expanding targeted therapy to NRAS-mutated melanoma.

Gibney GT, Weber JS. Gibney GT, et al. Lancet Oncol. 2013 Mar;14(3):186-8. doi: 10.1016/S1470-2045(13)70054-8. Epub 2013 Feb 13. Lancet Oncol. 2013. PMID: 23414591 No abstract available.

7

An unholy alliance: cooperation between BRAF and NF1 in melanoma development and BRAF inhibitor resistance.

Gibney GT, Smalley KS. Gibney GT, et al. Cancer Discov. 2013 Mar;3(3):260-3. doi: 10.1158/2159-8290.CD-13-0017. Cancer Discov. 2013. PMID: 23475878 Free PMC article.

8

Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies.

Gibney GT, Zager JS. Gibney GT, et al. Expert Opin Drug Metab Toxicol. 2013 Jul;9(7):893-9. doi: 10.1517/17425255.2013.794220. Epub 2013 Apr 29. Expert Opin Drug Metab Toxicol. 2013. PMID: 23621583 Review.

9

Paradoxical oncogenesis--the long-term effects of BRAF inhibition in melanoma.

Gibney GT, Messina JL, Fedorenko IV, Sondak VK, Smalley KS. Gibney GT, et al. Nat Rev Clin Oncol. 2013 Jul;10(7):390-9. doi: 10.1038/nrclinonc.2013.83. Epub 2013 May 28. Nat Rev Clin Oncol. 2013. PMID: 23712190 Free PMC article. Review.

10

Has targeted therapy for melanoma made chemotherapy obsolete?

Gibney GT, Sondak VK. Gibney GT, et al. Lancet Oncol. 2013 Jul;14(8):676-7. doi: 10.1016/S1470-2045(13)70298-5. Lancet Oncol. 2013. PMID: 23816289 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

93 results

Search Page